Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.

Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 oncoprotein, can effectively target HER2-positive breast cancer through several mechanisms. Although the effects of trastuzumab on cancer cell proliferation, angiogenesis and apoptosis have been invest...

Full description

Bibliographic Details
Main Authors:	Xiao-Feng Le, Maria I Almeida, Weiqun Mao, Riccardo Spizzo, Simona Rossi, Milena S Nicoloso, Shu Zhang, Yun Wu, George A Calin, Robert C Bast
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3400637?pdf=render

Similar Items

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
by: Huiping Li, et al.
Published: (2018-04-01)

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
by: Serena Di Cosimo, et al.
Published: (2020-02-01)

MicroRNA-194 inhibits epithelial-mesenchymal transition in human breast cancer cells
by: Jou-Chun Yang, et al.
Published: (2018)

MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12
by: Liang T, et al.
Published: (2016-07-01)

MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
by: Felicia C Huynh, et al.
Published: (2014-01-01)

MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer
by: Gao S, et al.
Published: (2018-08-01)

MicroRNA-194 modulates epithelial–mesenchymal transition in human colorectal cancer metastasis
by: Cai H, et al.
Published: (2017-02-01)

MicroRNA-194 Modulates Glucose Metabolism and Its Skeletal Muscle Expression Is Reduced in Diabetes.
by: Celine Latouche, et al.
Published: (2016-01-01)

Trastuzumab: More Than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells
by: Jiao Wang, et al.
Published: (2021-01-01)

MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1
by: Sudo Satoko, et al.
Published: (2011-08-01)

MicroRNA-194 Regulates Lipopolysaccharide-Induced Cell Viability by Inactivation of Nuclear Factor-κ B Pathway
by: Fei Xie, et al.
Published: (2017-10-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
by: Calin George A, et al.
Published: (2007-08-01)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
by: Daisuke Kotani, et al.
Published: (2021-01-01)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
by: Tiziana Triulzi, et al.
Published: (2019-01-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
by: Celia Nieto, et al.
Published: (2019-06-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
by: Justin M Scheer, et al.
Published: (2012-01-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
by: Alice Indini, et al.
Published: (2021-04-01)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
by: Tatiana Strava Corrêa, et al.
Published: (2018-05-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Alwin Jeyakumar, et al.
Published: (2012-01-01)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Alwin Jeyakumar, et al.
Published: (2012-04-01)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi S, et al.
Published: (2014-10-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)